查詢結果分析
相關文獻
- 新一代口服抗凝血劑
- Rivaroxaban新機轉之口服抗凝血劑
- 某醫院髖暨膝關節置換術之手術部位感染調查
- 傳明酸可有效降低全膝關節及髖關節置換術後的輸血量
- 執行全膝關節置換術、全髖關節置換術病人是否輸血與住院天數、醫療費用相關性探討
- 膝關節及髖關節手術部位的外科傷口感染
- 人工膝關節及髖關節置換術病患術後疼痛之分析
- Intramedullary Versus Extramedullary Tibial Alignment Guides in Total Knee Arthroplasty
- Revision Hip Arthroplasty for Aseptic Loosening: Three Years of Experience
- Risk Factors for Postoperative Femoral Fracture in Cementless Hip Arthroplasty
頁籤選單縮合
題 名 | 新一代口服抗凝血劑=The New Oral Anticoagulants |
---|---|
作 者 | 張芳瑀; | 書刊名 | 藥學雜誌 |
卷 期 | 29:1=114 2013.03[民102.03] |
頁 次 | 頁35-40 |
分類號 | 418.2321 |
關鍵詞 | 口服抗凝血劑; 髖關節置換術; 膝關節置換術; 靜脈血栓栓塞症; Oral anticoagulants; Total hip replacement; Total knee replacement; Venous thromboembolism; |
語 文 | 中文(Chinese) |
中文摘要 | 雖然 warfarin 早在1940年上市,臨床使用經驗已超過60年,但目前仍是唯一可口服的抗凝血藥品,其對於大部分血栓性疾病的預防與治療有好的效果,但治療濃度範圍狹窄、需抽血監測、易與藥品或食物產生交互作用而影響抗凝血效用等缺點,造成臨床使用上的不便。因此科學家積極地尋求替代藥品,開發了新的口服抗凝血藥品。目前三種新的口服抗凝血劑 (rivaroxaban、apixaban、dabigatran etexilate) 經過許多全球大型臨床試驗的考驗,已被多國國家核准上市,主要應用在預防靜脈血栓栓塞和心房顫動患者中風,未來在動脈血栓、急性冠心病的治療上也深具潛力。 |
英文摘要 | Since 1940, warfarin has remained the only oral form of anticoagulant medication approved for thromboembolic disease. Although it is highly effective for the prevention and/or treatment of most thrombotic disease, warfarin has a number of undesirable attributes: significant inter-and intra-patient variability in dose-response, a narrow therapeutic index, a slow pharmacodynamic response, and numerous interactions with both diet as well as other medications. The negative characteristics associated with warfarin have inspired many scientists to research and develop a new drug. Three new orally administered anticoagulants (apixaban, dabigatran etexilate, and rivaroxaban) are being studied for the prevention and treatment of venous thromboembolism, the treatment of acute coronary syndromes and the prevention of stroke in patients with atrial fibrillation. |
本系統中英文摘要資訊取自各篇刊載內容。